Lithium Aspartate for Long COVID Fatigue and Cognitive Dysfunction
JAMA Network Open · 02.10.2024 · 7 (10) · e2436874
DOI: 10.1001/jamanetworkopen.2024.36874 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JAMA Network Open, online erschienen am 02.10.2024. Verfasst von Thomas Guttuso und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Williamsville, New York. Hauptthemen laut MEDLINE: Fatigue, Cognitive Dysfunction, COVID-19, Aspartic Acid. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS.
Abstract (Originalsprache)
Importance Neurologic post–COVID-19 condition (PCC), or long COVID, symptoms of fatigue and cognitive dysfunction continue to affect millions of people who have been infected with SARS-CoV-2. There currently are no effective evidence-based therapies available for treating neurologic PCC.
Objective
To assess the effects of lithium aspartate therapy on PCC fatigue and cognitive dysfunction. Design, Setting, and Participants A randomized, double-blind, placebo-controlled trial (RCT) enrolling participants in a neurology clinic from November 28, 2022, to June 29, 2023, with 3 weeks of follow-up, was conducted. Subsequently, an open-label lithium dose-finding study with 6 weeks of follow-up was performed among the same participants enrolled in the RCT. Eligible individuals needed to report new, bothersome fatigue or cognitive dysfunction persisting for more than 4 weeks after a self-reported positive test for COVID-19, Fatigue Severity Scale-7 (FSS-7) or Brain Fog Severity Scale (BFSS) score of 28 or greater, Beck Depression Inventory-II score less than 29, and no history of a condition known to cause fatigue or cognitive dysfunction. All participants in the RCT were eligible for the dose-finding study, except for those who responded to the placebo. Intention-to-treat analysis was used.
Intervention
Lithium aspartate, 10 to 15 mg/d, or identically appearing placebo for 3 weeks followed by open-label lithium aspartate, 10 to 15 mg/d, for 2 weeks. In the subsequent dose-finding study, open-label lithium aspartate dosages up to 45 mg/d for 6 weeks were given. Main Outcomes and Measures Change in sum of FSS-7 and BFSS scores. The scores for each measure range from 7 to 49, with higher scores indicating more severe symptoms. Secondary outcomes included changes from baseline in the scores of additional questionnaires.
Results
Fifty-two participants were enrolled (30 [58%] males; mean [SD] age, 58.54 [14.34] years) and 26 were randomized to treatment with lithium aspartate (10 females) and 26 to placebo (12 female). Two participants assigned to lithium aspartate were lost to follow-up and none withdrew. No adverse events were attributable to lithium therapy. There were no significant intergroup differences for the primary outcome (−3.6; 95% CI, −16.6 to 9.5; P = .59) or any secondary outcomes. Among 3 patients completing a subsequent dose-finding study, open-label lithium aspartate, 40 to 45 mg/d, was associated with numerically greater reductions in fatigue and cognitive dysfunction scores than 15 mg/d, particularly in 2 patients with serum lithium levels of 0.18 and 0.49 mEq/L compared with 1 patient with a level of 0.10 mEq/L. Conclusions and Relevance In this RCT, therapy with lithium aspartate, 10 to 15 mg/d, was ineffective for neurologic PCC fatigue and cognitive dysfunction. Another RCT is required to assess the potential benefits of higher lithium dosages for treating neurologic PCC. Trial Registration ClinicalTrials.gov Identifier: NCT05618587 and NCT06108297
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Williamsville, New York.
- Department of Biostatistics, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Williamsville, New York.
Förderung
- NCATS NIH HHS
Zitieren
APA
Guttuso, T., Zhu, J., & Wilding, G. E. (2024). Lithium Aspartate for Long COVID Fatigue and Cognitive Dysfunction. JAMA Network Open, 7(10), e2436874. https://doi.org/10.1001/jamanetworkopen.2024.36874
Vancouver
Guttuso T, Zhu J, Wilding GE. Lithium Aspartate for Long COVID Fatigue and Cognitive Dysfunction. JAMA Network Open. 2024;7(10):e2436874. doi:10.1001/jamanetworkopen.2024.36874
BibTeX
@article{Guttuso2024,
author = {Guttuso, Thomas and Zhu, Jingtao and Wilding, Gregory E},
title = {Lithium Aspartate for Long COVID Fatigue and Cognitive Dysfunction},
journal = {JAMA Network Open},
year = {2024},
volume = {7},
number = {10},
pages = {e2436874},
doi = {10.1001/jamanetworkopen.2024.36874}
}
EUVIMED